Accelerate the Translation of Modulator & Treg Cell Therapies to Redefine Immune Tolerance for Autoimmune, Inflammatory, & Neurodegenerative Diseases
Not only is industry-defining clinical progression, with Coya Therapeutics' IND approval for FTD and PolTREG’s EMA qualification for marketing authorisation, elevating Treg therapies as a strategic priority, so now is investor confidence. With $50M of investment for Trex Bio and $11M for Coya Therapeutics in January alone, the momentum is unmistakable.
At the 8th Treg-Directed Therapies Summit; Quell Therapeutics, Nektar Therapeutics, Bristol Myers Squibb, Stanford University and more, converge to overcome key challenges from cell targeting, Treg mechanisms of action and cytokine interactions, to GMP and regulatory uncertainty, expanding across indications, clinical trial design and established efficacy endpoints to push the boundaries of Treg application and clinical success.
Over three action-packed days, enjoy industry-tailored, NEW data presentations from 10 companies , and interactive sessions led by pioneers unveiling their path to success, to benchmark against the community.
Understanding and manipulating Tregs for the development of immunotherapy in autoimmune diseases, transplantation and cancer hold great promise for these patients. This summit is an ideal platform to learn and exchange the updated information and knowledge in the field.
Wanjun Chen, Senior Investigator, NIH
This meeting combined leading professionals in the Treg field and provided the opportunity to communicate on what is happening in the field and take key learnings back to the team.
Hong Jiang, Chief Scientific Officer, Avotres
I loved the content and particularly enjoyed that the presentations that covered Treg related therapies from early development to manufacturing and clinical development.
Zengli Guo, Associate Director, AstraZeneca
Attending Companies Include
Explore the Full Event Guide
- A streamlined, single-track agenda so you can catch every session
- The Treg Biology Focus Day to deepen mechanistic insights & accelerate translational impact
- 9 hours of networking, to be on a first-name basis with experts in the Treg community
- C-suite led panel discussions revealing real-world strategies and perspectives from the industry's top decision makers
- Exclusive new data presentations
- A 75% new speaker faculty, bringing fresh perspectives to the stage
Official Partners
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.